• Skip to main content
  • Skip to footer
UK Plans to phase out animal testing UK Plans to phase out animal testing
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® Core Microphysiological System
    • Consumables
      • PhysioMimix® Multi-chip plates
      • 3D validated cells
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix Core

cnb1476_physiomimix-core_mark_mocks_system_v2
Learn more

Consumables

Multi-chip plates
3D validated cells
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the validated core application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

April 14, 2026

Event > Webinar >

Building regulatory confidence with immune-competent MPS


Discover how human liver models are building regulatory confidence in DILI risk assessment. How a continuously perfused, primary human Liver model, with immune-competent capabilities, can be leveraged to address a critical unmet need — capturing immune mediated toxicities associated with new drug modalities such as monoclonal antibodies (mAbs).

S9E2 Thumbnail | Regulatory confidence with immune-competent MPS
26 May 2026
08:00 (LA)| 10:00 (NY)| 15:00 (UK)
Virtual
Sign up here!

The US FDA’s 2025 roadmap to reduce reliance on animal testing has accelerated the adoption of human‑relevant new approach methodologies (NAMs), including microphysiological systems (MPS). Central to this transition is the requirement for qualified models with defined contexts of use and demonstrated predictive performance.

In this webinar, Emily Richardson and Justina Then will discuss how cross‑platform evaluations support the regulatory acceptance of non‑animal data, highlighting how immune‑competent liver MPS models capture immune‑mediated toxicities associated with new drug modalities, such as monoclonal antibodies (mAbs).

Key Learning on how to build regulatory confidence with immune-competent MPS

  • Shifting regulatory frameworks and the accelerated acceptance of MPS for decision-making
  • Benchmarking liver MPS performance using data from an FDA-ISTAND –accepted cross-platform evaluation project
  • Achieving long-term in vitro safety insights with continuously perfused human liver microtissue systems
  • Utilizing immune-competent liver and lung platforms to capture human-specific toxicities that are poorly predicted by animal models

About the Presenter:

Emily USE THIS ONE | Regulatory confidence with immune-competent MPS

Dr. Emily Richardson

Biology Group Leader

Dr. Emily Richardson is driving development of MPS for toxicology and safety assessment. She led the development of CN Bio’s Lung and Lung/Liver models for infectious disease research and inhaled therapeutics, and spearheaded multiple other collaborative and grant-funded programmes, published peer-reviewed papers, and contributed to advancing regulatory acceptance of Organ-on-a-chip.
Her work bridges complex cell biology and real-world drug discovery, informed by a PhD from the University of Leicester in 3D cell culture for metastatic lung cancer and a BSc in Biochemistry and Molecular Medicine degree from the University of Nottingham.
    justina BW

    Dr. Justina Then

    Senior Scientist

    Dr. Justina Then is a senior scientist at CN Bio, focusing on liver toxicology within the R&D team. Her academic foundation includes a PhD in experimental medicine and rheumatology and postdoctoral work at the William Harvey Research Institute (QMUL), where she spent her time investigating the potential of nanotechnology for drug development in rheumatoid arthritis and synovial fibroblasts.
    With nine years in academia and three years in industry, she brings a wealth of expertise to advancing biological research and practical applications.

      Building regulatory confidence with immune-competent MPS

      Sign up here!

      Speak to our experts

      Request a meeting with one of our OOC experts to see how our products and services can support your studies

      Request a meeting

      Footer

      CN Bio logo

      332 Cambridge Science Park, Milton Road
      Cambridge, CB4 0WN

      UK: +44 (0) 1223 737 941

      US: +1 415 523 4005

      Privacy | Cookies | Regulatory | Accessibility
      Website terms | Terms of sale

      Product Recycling

      ©2025 CN Bio Innovations Ltd
      Registered No. ‍06517359. VAT No. GB978184563

      Latest news

      • Do MHRA and FDA guidelines on non-animal methods in drug development align? March 27, 2026
      • CN Bio to participate in 3Rs Collaborative-led project with FDA to build confidence in Liver MPS for DILI – now ISTAND accepted! January 25, 2026
      • Taking organoids to the next level January 14, 2026
      Cyber Essentials Logo

      Modal Title